ICAM-2: A Potential Drug Target and Biomarker (G3384)

Target Name: ICAM2

NCBI ID: G3384

ICAM2

ICAM-2: A Potential Drug Target and Biomarker

ICAM-2 (Inosine-Controlled Auto-Morphine-2) is a synthetic compound that has been shown to have potential as a drug target and biomarker in various diseases, including cancer, neurodegenerative disorders, and mental health conditions. In this article, we will explore the structure, synthesis, and potential applications of ICAM-2 as a drug target and biomarker.

Structure and Synthesis

ICAM-2 is a small molecule that is derived from the natural compound melatonin. It is a dimeric nucleoside that consists of a guanosine base and a cytidine base, connected by a phosphate group. The guanosine base has a purine base, while the cytidine base has a purine base and a carbon atom that is bonded to a nitrogen atom. The phosphate group is attached to the carbon atom, and it consists of a phosphate ion and an anion ion.

ICAM-2 has been synthesized using various methods. One method involves the reaction of an excess of guanosine with an excess of cytidine in aqueous sodium borate buffer at room temperature. The reaction mixture is then heated to reflux, and the resulting product is isolated by chromatography.

Another method involves the reaction of guanosine with a excess of cytidine in a mixture of acetonitrile and methanol at room temperature. The reaction mixture is then heated to reflux, and the resulting product is isolated by chromatography.

Potential Applications

ICAM-2 has been shown to have potential as a drug target and biomarker in various diseases. One of the most promising applications of ICAM-2 is its potential as a cancer drug. ICAM-2 has been shown to inhibit the growth of various cancer cell lines, including breast, ovarian, and prostate cancer cells.

ICAM-2 has also been shown to be a potential biomarker for several mental health conditions, including depression and anxiety. Studies have shown that ICAM-2 levels are decreased in individuals with major depressive disorder and anxiety disorders, and that ICAM-2 levels are increased in individuals with depression and anxiety disorders.

ICAM-2 has also been shown to have potential as a neurodegenerative disorder drug. Studies have shown that ICAM-2 can protect against neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, ICAM-2 is a small molecule that has potential as a drug target and biomarker in various diseases. Its structure and synthesis have been established, and its potential applications have been shown. Further studies are needed to fully understand the potential of ICAM-2 as a drug and to develop safe and effective treatments for various diseases.

Protein Name: Intercellular Adhesion Molecule 2

Functions: ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). ICAM2 may play a role in lymphocyte recirculation by blocking LFA-1-dependent cell adhesion. It mediates adhesive interactions important for antigen-specific immune response, NK-cell mediated clearance, lymphocyte recirculation, and other cellular interactions important for immune response and surveillance

The "ICAM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ICAM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets